XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality.
• Current treatments for advanced HCC, such as multikinase inhibitors, have limited efficacy and significant side effects.
• Immunotherapy options are currently available only for a small subset of HCC patients.

Purpose of the Study:

• To evaluate the efficacy and safety of XON9, a novel glyco-humanized polyclonal antibody (GH-pAb), as a potential immunotherapy for hepatocellular carcinoma (HCC).

Main Methods:

• In vitro assessment of XON9's cytotoxic activity against HCC cell lines (Hep3B, Huh7, HepG2) and primary hepatocytes.
• Evaluation of apoptosis, caspase activity, reactive oxygen species (ROS) production, and mitochondrial membrane potential (MMP) in HCC cells.
• In vivo efficacy studies in mice and pharmacokinetic/safety assessments in non-human primates.

Main Results:

• XON9 exhibited potent complement-dependent cytotoxicity (CDC) against Hep3B and Huh7 HCC cell lines.
• XON9 induced apoptosis in HCC cells by activating caspases, increasing ROS, and reducing MMP.
• In vivo studies showed XON9 significantly reduced tumor progression and outperformed Sorafenib with no observed toxicity in primates.

Conclusions:

• XON9 demonstrates superior in vitro and in vivo efficacy compared to Sorafenib for HCC treatment.
• XON9 is a promising, selective immunotherapy agent for refractory hepatocellular carcinoma.
• The safety profile of XON9 in non-human primates suggests its potential for clinical development.